Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 4OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 49Prostatic Neoplasms 38Carcinoma, Non-Small-Cell Lung 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms 23Multiple Myeloma 22Lymphoma 21Leukemia, Myeloid, Acute 17Colorectal Neoplasms 17Melanoma 15Lung Neoplasms 13Hodgkin Disease 11Brain Neoplasms 11Medulloblastoma 10Lymphoma, Non-Hodgkin 10Glioblastoma 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Neoplasm Metastasis 9Leukemia, Biphenotypic, Acute 9Leukemia 9Head and Neck Neoplasms 9HIV Infections 9Neuroblastoma 8Hematologic Neoplasms 8Ependymoma 8Glioma 7Carcinoma, Renal Cell 7Astrocytoma 7Wilms Tumor 6

Interventions

Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Metastatic Hormone-sensitive Prostate Cancer × 1 year × Clear all
NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡